Stephen Liu, Chief, Division of Hematology and Oncology at Georgetown Lombardi Comprehensive Cancer Center, shared on X:
“Report on zongertinib and CNS disease in patients with advanced HER2 mutant NSCLC on JTO and JTO CRR. In 4 cases, patients received escalated doses of zongertinib at 240mg with variable effect but one case was able to continue at the higher dose for 30 months.”
Title: Brief report: Clinical use of zongertinib in patients with HER2 mutated NSCLC with brain metastases with or without leptomeningeal disease
Authors: Sakthi Kumar, Suresh S. Ramalingam, Ticiana Leal, Jennifer W. Carlisle
You can also read:
Rob Swanda Explains How Hernexeos (Zongertinib) Works for HER2‑Mutant NSCLC
